Research funder · United States
Alzheimer's Drug Discovery Foundation
Nonprofit organization
- Grants since 2016
- 326
- Awarded, last 5 years (where amounts are published)
- $245.1M
- Funded works, last 5 years
- 1 178
- Funded works, all time
- 2 272
Grants
2021–2024 · research · Drug Discovery
Preclinical efficacy study for antibody therapy in C9orf72 FTD/ALS mice
Dieter Edbauer · German Center for Neurodegenerative Diseases
2021 · conference · Conferences/Other
AFTD Patient-Focused Drug Development meeting with the FDA
Susan Dickinson · Association for Frontotemporal Degeneration
2021 · research · Diagnostics Accelerator
Diagnostics Accelerator Speech & Language Consortium: Harmonized Repository for the Exploration of Speech and Language Biomarkers for Neurodegenerative Disease
Mobility Consulting Group, Llc
2021–2022 · research · Drug Discovery
Preserving NPTX2 and Memory in Alzheimer's Disease
Paul Worley · Johns Hopkins University
2021–2026 · research · Diagnostics Accelerator
Identifying an ophthalmic combinatorial biomarker of early Alzheimer’s disease using novel imaging and deep learning
Cecilia Lee · University of Washington
2021–2025 · prize · Clinical
2019 Annual Goodes Prize for Excellence in Alzheimer’s Drug Discovery: Rasagiline Rescue in Alzheimer’s Disease Clinical Trial (R2 Trial) – Biomarker add-on funding
Jeffrey Cummings · University of Nevada, Las Vegas
2021–2022 · research · Diagnostics Accelerator
Validation and commercialization of a novel blood-based, ultra-multiplex Laboratory Developed Test (LDT) for the prediction of cerebral amyloid status before clinical onset of dementia.
Leyla Anderson · Neurovision Imaging, Inc.
2021–2026 · research · Diagnostics Accelerator
Plasma pathologic TDP-43 as a biomarker for FTLD-TDP
Qinwen Mao · University of Utah
2021–2022 · research · Drug Discovery
Lead Optimization of Novel Site-Selective Blockers of Mitochondrial Complex III ROS as FTD Therapeutics
Anna Orr · Cornell University
2021 · conference · Conferences/Other
Clinical Trials for Alzheimer’s Disease CTAD
Nathanaelle Touchon · Clinical Trials For Alzheimer's Disease Congress
2021–2022 · research · Clinical
A single-center, randomized, placebo-controlled single and multiple ascending dose study in healthy male and female subjects to study the safety, tolerability, food effect, pharmacokinetics and target engagement of the second-generation O-GlcNAcase inhibitor ASN121151
Dirk Beher · Asceneuron Sa
2020–2023 · prize · Drug Discovery
2020 Annual Goodes Prize for Excellence in Alzheimer’s Drug Discovery: Development of mGlu5 negative or silent allosteric modulators for the treatment of Alzheimer’s disease
Jerri Rook · Vanderbilt University
2020–2022 · research · Biomarkers
Validating magnetic susceptibility as a biomarker for iron-related oxidative stress and white matter changes in AD
Chunlei Liu · University of California, Berkeley
2020–2021 · research · Biomarkers
Multi-class classifier for CNS Disorder type and Alzheimer’s Disease progression
David Salzman · Gatehouse Bio, Inc.
2020–2021 · research · Biomarkers
Targeting macrophage colony stimulating factor receptor one (CSF1R) as a PET imaging biomarker for Alzheimer’s disease
Martin Pomper · Precision Molecular Inc.
2020–2022 · research · Drug Discovery
Development of Small Molecules Modulators of Mitochondrial Function
Eugenia Trushina · Mayo Clinic
2020–2023 · research · Clinical
Dopaminergic Therapy for Frontotemporal Dementia Patients.
Giacomo Koch · Fondazione Santa Lucia
2020 · prize · Clinical
2019 Annual Goodes Prize for Excellence in Alzheimer’s Drug Discovery: Rasagiline Rescue in Alzheimer’s Disease Clinical Trial (R2 Trial) – Biomarker add-on funding
Jeffrey Cummings · Lou Ruvo Brain Institute
2020–2025 · research · Diagnostics Accelerator
Plasma Aβ as a Predictor of Amyloid Positivity in Alzheimer’s Disease
Sri Pullagura · Foundation For The National Institutes Of Health, Inc.
2020–2022 · conference · Conferences/Other
Dementia Nomenclature Initiative (DeNomI)
Angela Taylor · Lewy Body Dementia Association, Inc.
2020–2022 · research · Diagnostics Accelerator
ELISA assay for cleaved high molecular weight kininogen (HKc) as a diagnostic tool for Alzheimer’s disease (AD)
Sidney Strickland · Rockefeller University
2020–2025 · research · Clinical
Phase I Clinical Trial for the AAV mediated treatment of APOE4 homozygous Alzheimer’s Disease
Ronald Crystal · Lexeo Therapeutics, Inc.
2020–2023 · research · Diagnostics Accelerator
Quantitative Profiling of Proteopathy-associated Proteins and their Fragments in Blood to Diagnose AD and FTD and to Monitor Treatment Response
Judith Steen · Boston Children's Hospital
2020–2021 · research · Diagnostics Accelerator
Blood diagnostic test for AD: aptamer deep biomarker fingerprinting
Gregory Penner · Neoneuro
2020–2023 · research · Biomarkers
Clinical Validation and Accreditation for Plasma Aß42/Aß40 as a Biomarker for Alzheimer’s Disease Pathology
Kevin Yarasheski · C2N Diagnostics (United States)
2020–2021 · research · Diagnostics Accelerator
ADmit Test: a new kit for an early Alzheimer's disease detection
Marta Barrachina · Admit Therapeutics S.l.
2020–2022 · research · Clinical
Non-Invasive Brain Stimulation for Gamma Induction and Cognitive Enhancement in FTD
Emiliano Santarnecchi · Harvard University
2020 · conference · Conferences/Other
GAP Foundation Innovation Summit in Washington D.C.
John Dwyer · Global Alzheimer's Platform Foundation
2020–2023 · research · Diagnostics Accelerator
NOVEL VIRTUAL REALITY METHOD TO DISTINGUISH APATHY FROM DEPRESSION IN THE CONTEXT OF DEMENTIA
Ramit Ravona-Springer · Sheba Medical Center
2020–2023 · research · Diagnostics Accelerator
Non-invasive detection of brain cell death using methylation patterns of circulating DNA: a novel blood test for early detection of Alzheimer’s Disease
Yuval Dor · Hebrew University of Jerusalem
2020 · conference · Conferences/Other
Clinical Trials for Alzheimer's Disease (CTAD) Digital Conference
Nathanaelle Touchon · Clinical Trials For Alzheimer's Disease Congress
2020–2026 · research · Diagnostics Accelerator
Machine Learning Technologies for Advancing Digital Biomarkers for Alzheimer's Disease
Guoliang Xing · Chinese University of Hong Kong
2020–2021 · research · Diagnostics Accelerator
Development and Commercialization of a Protein Misfolding Cyclic Amplification (PMCA) Clinical Test for Detection of Aggregates of Misfolded α-Synuclein in Plasma and Plasma Exosomes
Russell Lebovitz · Amprion (United States)
2020–2021 · research · Drug Discovery
Preclinical pharmacokinetics and pharmacodynamics of CT-526 in the tauopathy mouse model
John "Kent" Werner · Cogentis Therapeutics
2020–2026 · research · Diagnostics Accelerator
International Shopping List Mobile Test
Pam Ventola · Cogstate Ltd
2020–2024 · research · Diagnostics Accelerator
Novel Platform for on-chip Detection of Neuronal Extracellular Vesicles Biomarkers for Alzheimer Disease in Plasma
Mary Esola · Biological Dynamics, Inc
2019–2021 · research · Diagnostics Accelerator
TABLOOD: a biomarker panel for direct assessment in blood of Alzheimer’s Disease pathophysiological hallmarks.
Douglas Galasko · University of California San Diego
2019–2023 · research · Diagnostics Accelerator
Retinal Changes in Alzheimer’s disease (AD) Correlated with Cerebral Amyloid Staging, A Promising Early Biomarker in AD
Eliav Shaked · Retispec Inc.
2019–2022 · research · Biomarkers
Cerebrovascular Disease & Clinical Trials in AD: Cognitive Outcomes, Biomarker Outcomes, & Optimal Set of Features
Clifford Jack · Mayo Clinic
2019–2020 · research · Drug Discovery
SUMO2 mimetics as innovative Inhibitors of Tau toxicity in Pre-clinical Models of Frontotemporal Dementia
Luana Fioriti · Plico Biotech Inc